Obesity - rimonabant (withdrawn)
Rimonabant for the treatment of overweight and obese patients
Summary
The European Medicines Agency (EMEA), the European Union (EU) body which is responsible for monitoring the safety of medicines, has recommended the suspension of the marketing authorisation for rimonabant (acomplia) from Sanofi-Aventis. The EMEA has concluded that the benefits of rimonabant no longe ...
As a result of the EMEA's decision, NICE has temporarily withdrawn its guidance on the use of rimonabant for the treatment of overweight and obese patients. NICE will continue to review the status of its guidance in light of any further changes to rimonabant's marketing authorisation.
Further information on the EMEA's decision is available from its website.
Guidance documents
Implementing this guidance
We will consult on our review plans for this guidance in April 2010
About this guidance
Technology appraisals TA144
Issued: June 2008